These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 24054719

  • 1. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH, Chi HS, Cho YU, Jang S, Park CJ.
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
    Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S.
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1845-50. PubMed ID: 22766221
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS, Hu YL, Guan LX, Peng B, Wang SY.
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [Abstract] [Full Text] [Related]

  • 8. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group.
    N Engl J Med; 2008 May 01; 358(18):1909-18. PubMed ID: 18450602
    [Abstract] [Full Text] [Related]

  • 9. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
    Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Kanamori H, Usuki K, Uoshima N, Yanada M, Takeuchi J, Mizuno I, Kanda J, Okamura H, Yano S, Tashiro H, Shindo T, Chiba S, Tomiyama J, Inokuchi K, Fukuda T.
    Int J Hematol; 2020 Aug 01; 112(2):200-209. PubMed ID: 32495317
    [Abstract] [Full Text] [Related]

  • 10. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K, AML CG study group.
    Ann Hematol; 2012 Jul 01; 91(7):1051-63. PubMed ID: 22362118
    [Abstract] [Full Text] [Related]

  • 11. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, Bohlander SK, Braess J, Heinecke A, Sauerland MC, Berdel WE, Buechner T, Woermann BJ, Feuring-Buske M, Buske C, Creutzig U, Thiede C, Zwaan MC, van den Heuvel-Eibrink MM, Reinhardt D, Hiddemann W, Spiekermann K.
    Ann Hematol; 2012 Jan 01; 91(1):9-18. PubMed ID: 21744003
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
    Ruan M, Zhang L, Han C, Liu X, Ai X, Zhang J, Liu T, Yang W, Chen X, Guo Y, Wang S, Li Q, Zou Y, Chen Y, Zhu X.
    Zhonghua Er Ke Za Zhi; 2014 Apr 01; 52(4):303-7. PubMed ID: 24915920
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis.
    Port M, Böttcher M, Thol F, Ganser A, Schlenk R, Wasem J, Neumann A, Pouryamout L.
    Ann Hematol; 2014 Aug 01; 93(8):1279-86. PubMed ID: 24801015
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H, Li XQ, Chu TT, Han SY, Qi JQ, Tang YQ, Qiu HY, Fu CC, Tang XW, Ruan CG, Wu DP, Han Y.
    J Cancer Res Clin Oncol; 2021 Sep 01; 147(9):2659-2670. PubMed ID: 33550446
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
    Su L, Gao SJ, Li W, Tan YH, Cui JW, Hu RP.
    Hematology; 2014 Sep 01; 19(6):324-8. PubMed ID: 24164801
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U.
    Eur J Haematol; 2008 Mar 01; 80(3):208-15. PubMed ID: 18081718
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.
    Wen XM, Lin J, Yang J, Yao DM, Deng ZQ, Tang CY, Xiao GF, Yang L, Ma JC, Hu JB, Qian W, Qian J.
    Int J Clin Exp Pathol; 2014 Mar 01; 7(10):6832-40. PubMed ID: 25400766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.